Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.50 |
| ▸ | RAF1 | P04049 | 14/20 | 0.46 |
| ▸ | BRAF | P15056 | 14/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639236 | 0.85 | MAPK14 (0.52) | LCKMAPK14BRAFRIPK1RIPK3 | |
| SCHEMBL14108034 | 0.79 | MAPK14 (0.54) | LCKMAPK14RAF1BRAFRIPK1 | |
| SCHEMBL3585208 | 0.78 | LCK (0.43) | LCKMAPK14RIPK1RIPK3KDR | |
| SCHEMBL4639353 | 0.77 | MAPK14 (0.58) | LCKMAPK14RAF1BRAFRIPK1 | |
| SCHEMBL3574150 | 0.75 | SMN1; SMN2 (0.45) | LCKMAPK14RIPK1RIPK3MAPK8 | |
| SCHEMBL3579827 | 0.75 | AURKA (0.43) | LCKMAPK14RIPK1RIPK3JAK3 | |
| SCHEMBL3581924 | 0.74 | CNR2 (0.43) | LCKMAPK14BRAFKDR | |
| SCHEMBL3663799 | 0.74 | LCK (0.40) | LCKMAPK14RIPK1RIPK3KDR | |
| SCHEMBL2974025 | 0.73 | LCK (0.69) | LCKMAPK14RAF1KDRSRC | |
| SCHEMBL4620357 | 0.72 | LCK (0.77) | LCKMAPK14RAF1BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1893605-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006103449-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | TIE1, TEK, FLT1 | LCK 902/4885MAPK14 3097/4885RAF1 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.